Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "European urology focus"
DOI: 10.1016/j.euf.2020.10.009
Abstract: BACKGROUND The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes in patients with a partial response or the benefit of… read more here.
Keywords: atezolizumab treated; partial response; response; treated patients ... See more keywords
Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.862752
Abstract: Background Development of severe immune-related adverse events (irAEs) is a major predicament to stop treatment with immune checkpoint inhibitors, even though tumor progression is suppressed. However, no effective early phase biomarker has been established to… read more here.
Keywords: test biomarkers; atezolizumab treated; blood test; test ... See more keywords